AstraZeneca hits back as investor backs public interest test for Pfizer takeover

Firm forecasts 75% rise in revenue by 2023 as Martin Gilbert flags up UK science role and others fears over Pfizer cost-cutting

AstraZeneca has hit back following an unwanted £63bn takeover approach from Pfizer by setting out a new growth plan that targets a 75% rise in annual revenue by 2023. The release came as one of the group’s top 10 shareholders backed Labour leader Ed Miliband’s call for a public interest test in big foreign takeovers, and a former AstraZeneca boss warned Pfizer could act like a praying mantis and "suck the lifeblood out of its prey".

Continue reading…
Pharmaceuticals industry | The Guardian

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us